Myc

Where the papers sit

13 papers from the last 6 months study myc directly · updated from PubMed 30 Oct 2026

• MYC-Linked Disease Mechanisms

  MYC-centered mechanisms recur across cancer, tissue injury and degeneration rather than forming one clinical program. Protein degradation, mitophagy, glycolytic reprogramming and ferroptosis appear as recurring biological levers. A stapled MYC degrader is being explored in triple-negative breast cancer, while FTH1 and GPX4 connect MYC to oxaliplatin resistance. Multi-omics studies nominate EGFR, AKT1 and CXCL8, but therapeutic convergence remains open.

  8 papers · 61.5%

• Oncogene-Driven Tumor Genomics

  Molecular profiling links aggressive lymphoma and sarcoma to actionable oncogenic alterations. High-grade B-cell lymphoma work emphasizes BCL6, BCL2, relapse patterns and rearrangements detected by Hi-C. Sarcoma PDX studies highlight ecDNA-driven amplification and KRAS-associated biology. The field is moving toward integrated genomic diagnosis and PDX-supported treatment selection.

  3 papers · 23.1%

• MYC-Driven Lymphoma Therapy

  MYC-driven Burkitt lymphoma is linked to both unusual paraneoplastic muscle disease and targeted protein degradation. One report highlights myopathy as a possible initial presentation, alongside diagnostic and CNS-prophylaxis concerns. Preclinical work pairs MYC degradation with GSPT1 degradation for hematologic malignancies. The shared direction is toward biologically targeted therapy while clinical recognition of atypical presentation remains important.

  2 papers · 15.4%